Cytisine analogs led to varenicline at Pfizer.Varenicline received a "priority review" by the US FDA in February 2006, shortening the usual ten-month review period to six months because of its demonstrated effectiveness in clinical trials and perceived lack of safety issues. The agencys approval of the drug came on May 11, 2006. On September 29, 2006, it was approved for sale in the European Union.On September 16, 2021, Pfizer announced a recall of "all lots of its anti-smoking treatment, Chantix [Varenicline], due to high levels of cancer-causing agents called nitrosamines in the pills". This followed a July 2, 2021 announcement by the FDA that it was "alerting patients and health care professionals to Pfizers voluntary recall of nine lots of the smoking cessation drug" and further recalls by Pfizer on July 19 and Aug. 8. On June 24, Pfizer had paused distribution of Chantix worldwide; "[t]he distribution halt [wa]s out of an abundance of caution, pending further testing, the company said in an email. According to the Pfizer Inc. 2020 Form 10-K Annual Report, high-revenue products by the company include[d] Chantix/Champix (varenicline) to treat nicotine addiction, [which] had $919 million in 2020 revenues.In October 2021, US FDA approved Oyster Point Pharma to market Tyrvaya as a new route of varenicline administration through nasal spray for the treatment of dry eye disease. References
External links
"Varenicline". Drug Information Portal. U.S. National Library of Medicine.
Platelet storage pool deficiency is a type of coagulopathy characterized by defects in the granules in platelets, particularly a lack of granular non-metabolic adenosine diphosphate. Individuals with adenosine diphosphate deficient storage pool disease present a prolonged bleeding time due to impaired aggregation response to fibrillar collagen. Symptoms and signs
The presentation (signs/symptoms) of an individual with  platelet storage pool deficiency is as follows:
Unusual bleeding(after surgical procedure)
Anemia
Decrease mean platelet volume
Myelodysplasia

Cause
The condition of platelet storage pool deficiency can be acquired  or inherited (genetically passed on from the individuals parents). Some of the causes of platelet storage pool deficiency when acquired are:
Hairy-cell leukemia
Cardiovascular bypass

Mechanism
In terms of the pathophysiology of platelet storage pool deficiency one must consider several factors including the human bodys normal function prior to such a deficiency, such as platelet alpha-granules one of three types of platelet secretory granulePlatelet α–granules are important in platelet activity, α–granules connect with plasma membrane. This in turn increases the size of the platelet. Platelet α–granules have an important role in hemostasis as well as thrombosis. SNARE accessory proteins control the secretion of α–granule. Diagnosis
The diagnosis of this condition can be done via the following:
Flow cytometry
Bleeding time analysis
Platelet aggregation function study:

Types
This condition may involve the alpha granules or the dense granules. Therefore, the following examples include:

Platelet alpha-granules
Gray platelet syndrome
Quebec platelet disorder
Dense granules
δ-Storage pool deficiency
Hermansky–Pudlak syndrome
Chédiak–Higashi syndrome

Treatment
Platelet storage pool deficiency has no treatment however management consists of antifibrinolytic medications if the individual has unusual bleeding event, additionally caution should be taken with usage of NSAIDS

See also
Hypocoagulability
Hypercoagulability

References
Further reading
Sandrock, Kirstin; Zieger, Barbara (2010).